Increased Expression of LMCD1 in Scleroderma-Associated Interstitial Lung Disease is Critical for Profibrotic Characteristics of Lung Myofibroblasts.
Galina S BogatkevichIlia AtanelishviliAndrew M BogatkevichRichard M SilverPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
Our study identifies LMCD1 as a profibrotic molecule contributing to the activation of myofibroblasts and the persistent fibroproliferation observed in SSc-ILD. Thus, LMCD1 may be a potential novel therapeutic target for patients with SSc-ILD. This article is protected by copyright. All rights reserved.